About Us
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
|
|
Previous Close | $3.16 | Open | $3.05 |
Volume | 174.3K | Market Cap | 9.68M |
Yield | Last Dividend |
Cancer Genetics to Present at the 2021 B... | 01/07/21 |
RUTHERFORD, N.J., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (the ???Company???) (Nasdaq: CGIX), an emerging leader in novel drug discove... |
Cancer Genetics, Inc. Increases Previous... | 10/28/20 |
Rutherford, N.J., Oct. 28, 2020 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq: CGIX) (???Cancer Genetics???), a leader in drug discovery and precl... |
CANCER GENETICS INVESTOR ALERT by the Fo... | 08/26/20 |
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (???KSF???) a... |
The Daily Biotech Pulse: Altimmune Repor... | 08/25/20 |
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 24) Abbott Laboratories (NYSE: ABT ) Cancer Genetics Inc (NASDAQ: CGIX ) (announced a dea... |
Cancer Genetics Merger Investigation: Ha... | 08/25/20 |
NEW YORK, Aug. 25, 2020 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, is investigating whether Cancer Genetics, Inc. (NASDAQ: C... |
Why Cancer Genetics Is Trading Higher To... | 08/24/20 |
Cancer Genetics (NASDAQ: CGIX ) shares are trading higher on Monday after the company announced the entry into a definitive merger agreement with Stem... |
Cancer Genetics Reports First Quarter 20... | 06/24/20 |
RUTHERFORD, N.J., June 24, 2020 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (the ???Company???) (Nasdaq: CGIX), a leader in drug discovery and preclinic... |
The Daily Biotech Pulse: Mylan Ramps Up ... | 03/20/20 |
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs March 19.) ... |
The Daily Biotech Pulse: Endo's Cellulit... | 11/20/19 |
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Nov. 19) ... |
The Daily Biotech Pulse: Therapix To Rev... | 11/19/19 |
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Nov. 18) ... |
Cancer Genetics Announces 1-for-30 Rever... | 10/24/19 |
Cancer Genetics, Inc. (CGIX), a leader in drug discovery and preclinical oncology and immuno-oncology services, today announced that it will effect a ... |
The Daily Biotech Pulse: EC Nod For Bris... | 08/28/19 |
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Aug. 27) ... |
The Daily Biotech Pulse: Nuvectra Explor... | 08/27/19 |
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs on Aug. 26) ... |
The Daily Biotech Pulse: Mallinkckrodt's... | 08/15/19 |
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Aug. 14) ... |
The Daily Biotech Pulse: European Cheer ... | 07/30/19 |
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on July 29) ... |
The Daily Biotech Pulse: Jounce Jumps On... | 07/24/19 |
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on July 23) ... |
Cancer Genetics Sharply Higher After Int... | 07/16/19 |
Cancer Genetics (NASDAQ: CGIX ) shares are trading sharply higher after Interpace Diagnostics (NASDAQ: IDXG ) said it purchased the Biopharma Services... |
The Daily Biotech Pulse: Tocagen Tumbles... | 05/22/19 |
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs on May 21) A... |
Cancer Genetics beats by $0.02, beats on... | 04/16/19 |
Cancer Genetics (CGIX): Q4 GAAP EPS of -$0.14 beats by $0.02. Revenue of $6.8M (-9.3% Y/Y) beats by $0.5M. Shares +1.4% PM. Press Release |
Daily Insider Ratings Round Up - Feb. 1,... | 02/04/19 |
No summary available. |
Cancer Genetics announces pricing of com... | 01/29/19 |
No summary available. |
Cancer Genetics readies stock offering; ... | 01/28/19 |
No summary available. |
Daily Insider Ratings Round Up 1/16/19 | 01/18/19 |
No summary available. |
Daily Insider Ratings Round Up 1/16/19 | 01/18/19 |
No summary available. |
Cancer Genetics +16% on loan forbearance... | 01/16/19 |
No summary available. |
Cancer Genetics +16% on loan forbearance... | 01/16/19 |
No summary available. |
Cancer Genetics down 28% on pricing equi... | 01/10/19 |
No summary available. |
Cancer Genetics down 28% on pricing equi... | 01/10/19 |
No summary available. |
Cancer Genetics readies stock offering; ... | 01/09/19 |
No summary available. |
Cancer Genetics readies stock offering; ... | 01/09/19 |
No summary available. |
Date | 04/12/2019 (AMC) | Est. (EPS/Rev.) | $1.37 |
Actual (EPS/Rev.) | $2.5B | EPS (TTM) | $??? |
Total Revenue | $1.3B | Total Liabilities | $2.1B |
Cost of Revenue | $2.5B | Total cash flow | $3.2 |
Total Assets | $29.98B |
% Insider | 12.52% | % Institutional | 76.43% |
Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
Service Name | Trader | % Success | |
---|---|---|---|
Tech Trades | Tech Trades | 81.00 % | Follow |
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
We are not a registered investment advisor. All investments involve risk, individual's trading does not guarantee future results or returns. Investors are fully responsible for any investment decisions they make. References to specific securities should not be construed as a recommendation to buy or sell that security only mentioned for informational purposes.